Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVanc: Optimised vs Standard Vancomycin in Neonatal Sepsis
NCT02790996Phase 2Terminated
- Sponsor
- Penta Foundation
- Start
- Feb 2017
- Primary completion
- Apr 2020
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of vancomycin in late-onset neonatal sepsis (LONS), sponsored by Penta Foundation. Started Feb 2017; status: terminated.
02
Drugs
vancomycin
03
Conditions
late-onset neonatal sepsis (LONS)
Beyond the preview
Go deeper on NCT02790996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02790996.